Regeneron Pharma (REGN) Tops Q3 EPS Views; Raises FY12 EYLEA Net Sales Outlook

October 24, 2012 6:33 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q3 EPS of $1.89, $0.93 better than ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found